Spectrum Pharmaceuticals (SPPI) reported quarterly earnings results on Thursday, May-5-2016. The company said it had a profit of $0.01 Earnings per Share for the quarter. The results exceeded Wall Street expectations beating the analyst consensus estimate by $0.13. Analysts had a consensus of $-0.12. The company posted revenue of $43.90 million in the period, compared to analysts expectations of $28.83 million. The company’s revenue was up 13.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.07 EPS.
Spectrum Pharmaceuticals closed down -0.17 points or -2.38% at $6.96 with 5,78,708 shares getting traded on Wednesday. Post opening the session at $7.09, the shares hit an intraday low of $6.92 and an intraday high of $7.09 and the price fluctuated in this range throughout the day.Shares ended Wednesday session in Red.
Spectrum Pharmaceuticals Inc. is a biotechnology Company. The Company is engaged in commercial and drug development operations with a focus on hematology and oncology. The Company is engaged in acquiring developing and commercializing the pipeline of late-stage clinical and commercial drug compounds. The Company market five drugs for the treatment of cancer which includes FUSILEV injection for patients with advanced metastatic colorectal cancer and to counteract certain effects of methotrexate therapy; ZEVALIN injection for patients with follicular non-Hodgkin’s lymphoma; FOLOTYN injection for patients with relapsed or refractory peripheral T-cell lymphoma (PTCL); MARQIBO injection for patients with Philadelphia chromosomenegative acute lymphoblastic leukemia and BELEODAQ injection for patients with relapsed or refractory PTCL.